Status:
COMPLETED
Efficacy of Losartan in Preventing Progression of COPD
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Merck Sharp & Dohme LLC
Conditions:
COPD
Emphysema
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hyperte...
Detailed Description
Participants will be given either losartan in a dose of 50-100 mg per day for a period of one year. During that time, they will have lung function tests, breathing tests, and computed tomograms of the...
Eligibility Criteria
Inclusion
- Adults with COPD who are either active or former smokers
Exclusion
- Clinical requirement or history of intolerance of angiotensin receptor blockers, serious heart, liver, kidney, neurological disease.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00720226
Start Date
July 1 2008
End Date
August 1 2016
Last Update
April 25 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Asthma and Allergy Center
Baltimore, Maryland, United States, 21205